A 55-year-old obese woman with previous hypothyroidism had a myocardial infarction followed by sudden papillary muscle rupture and profound cardiac failure. A Medtronic mitral valve prosthesis was inserted as an emergency but she remained in severe left ventricular failure until eventually controlled on frusemide 100 mg/day, isosorbide mononitrate 10 mg bid, digoxin 125 jug once daily, and captopril 12.5 mg bid. She was also receiving warfarin because of the prosthetic valve, thryoxine 150 jug and prednisolone 7.5 mg daily for muscular pains (not associated with other symptoms) diagnosed two years earlier as possible polymyalgia rheumatica.
She was making good progress until four months later when she complained of malaise, myalgia and arthralgia, of feeling flushed and she was noted to have a persistent low grade pyrexia (37.5-38°C), a polymorphonuclear leucocytosis (white blood cell count 13 000, 80% neutrophils), and an erythrocyte sedimentation rate of 50 mm/h (previously steady around 35 mm/h). Endocarditis was considered in the differential diagnosis but extensive investigations over a four-week period including repeated blood cultures, virology screen, auto-antibodies, abdominal computed tomography (CT) scan, transoesophageal echocardiography, and white cell scan failed to detect any abnormality and a prolonged course of antibiotics (including cefuroxime, metronidazole and flucloxacillin) had no effect on her symptoms, temperature or leucocytosis.
At four weeks, she developed an erythema multiforme-like rash which persisted when the antibiotics were discontinued and it was decided that captopril would also be withdrawn. Within 48 hours, her temperature had fallen to 37°C for the first time in four weeks and she remained apyrexial, her malaise and myalgia disappeared, as did her rash and she was discharged home. Unfortunately, her cardiac failure slowly returned over the next few months and five months later, she was readmitted and enalapril was instituted at a dose of 10 mg mane and 5 mg nocte. She responded well to addition of this angiotensinconverting enzyme (ACE) inhibitor without recurrence of her malaise, myalgia, arthralgia, rash, leucocytosis or pyrexia. ACE inhibitor therapy has been a major advance in the treatment of heart failure and this woman who had profound left ventricular failure deteriorated markedly before an ACE inhibitor was re-introduced. Resolution of captopril-induced rash after substitution of enalapril has occurred'0 so we decided to introduce this drug. The failure of recurrence of symptoms and signs is suggestive of a specific and possibly type B (idiosyncratic) adverse reaction to captopril rather than a class 
